Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck

Benzer Materyaller

• A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer
  Yazar:: Lee, Keun-Wook, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer
  Yazar:: Argiris, Athanassios, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma
  Yazar:: Haddad, R.I., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer
  Yazar:: Saraswathula, Anirudh, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Commentary on “Weekly Low‐Dose Versus Three‐Weekly High‐Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non‐Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta‐Analysis of Aggregate Data”
  Yazar:: Colevas, A. Dimitrios
  Baskı/Yayın Bilgisi: (2017)